These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27922739)

  • 1. Tyrosine kinase, aurora kinase and leucine aminopeptidase as attractive drug targets in anticancer therapy - characterisation of their inhibitors.
    Ziemska J; Solecka J
    Rocz Panstw Zakl Hig; 2016; 67(4):329-342. PubMed ID: 27922739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aurora kinases as anticancer drug targets.
    Gautschi O; Heighway J; Mack PC; Purnell PR; Lara PN; Gandara DR
    Clin Cancer Res; 2008 Mar; 14(6):1639-48. PubMed ID: 18347165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on aurora kinase inhibitors in gynecologic malignancies.
    Tao X; Chon HS; Fu S; Kavanagh JJ; Hu W
    Recent Pat Anticancer Drug Discov; 2008 Nov; 3(3):162-77. PubMed ID: 18991785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-kinase inhibitors, AURKs and cancer.
    Cicenas J; Cicenas E
    Med Oncol; 2016 May; 33(5):43. PubMed ID: 27038473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aurora A and B kinases--targets of novel anticancer drugs.
    Libertini S; Abagnale A; Passaro C; Botta G; Portella G
    Recent Pat Anticancer Drug Discov; 2010 Nov; 5(3):219-41. PubMed ID: 20524930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aurora A and B kinases as targets for cancer: will they be selective for tumors?
    Matthews N; Visintin C; Hartzoulakis B; Jarvis A; Selwood DL
    Expert Rev Anticancer Ther; 2006 Jan; 6(1):109-20. PubMed ID: 16375648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer.
    Carmi C; Mor M; Petronini PG; Alfieri RR
    Biochem Pharmacol; 2012 Dec; 84(11):1388-99. PubMed ID: 22885287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Danusertib, an aurora kinase inhibitor.
    Meulenbeld HJ; Mathijssen RH; Verweij J; de Wit R; de Jonge MJ
    Expert Opin Investig Drugs; 2012 Mar; 21(3):383-93. PubMed ID: 22242557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aurora kinase inhibitors: progress towards the clinic.
    Kollareddy M; Zheleva D; Dzubak P; Brahmkshatriya PS; Lepsik M; Hajduch M
    Invest New Drugs; 2012 Dec; 30(6):2411-32. PubMed ID: 22350019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [ABL1, SRC and other non-receptor protein tyrosine kinases as new targets for specific anticancer therapy].
    Klener P; Klener P
    Klin Onkol; 2010; 23(4):203-9. PubMed ID: 20806817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting cancer with small-molecular-weight kinase inhibitors.
    Fabbro D; Cowan-Jacob SW; Möbitz H; Martiny-Baron G
    Methods Mol Biol; 2012; 795():1-34. PubMed ID: 21960212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents.
    Laird AD; Cherrington JM
    Expert Opin Investig Drugs; 2003 Jan; 12(1):51-64. PubMed ID: 12517254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor.
    Gontarewicz A; Brümmendorf TH
    Recent Results Cancer Res; 2010; 184():199-214. PubMed ID: 20072840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Tyrosine Kinases and their Inhibitors in Cancer Therapy: A Comprehensive Review.
    Kumar V; Kaur N; Sahu S; Sharma V; Kumar D; Sharma A; Wadhwa P
    Curr Med Chem; 2023; 30(13):1464-1481. PubMed ID: 35894454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of tyrosine kinase inhibitors in cancer therapy.
    Arora A; Scholar EM
    J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
    Johnson FM; Saigal B; Talpaz M; Donato NJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of Aurora kinase inhibitors in cancer.
    Naruganahalli KS; Lakshmanan M; Dastidar SG; Ray A
    Curr Opin Investig Drugs; 2006 Dec; 7(12):1044-51. PubMed ID: 17209521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
    Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
    Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a future for Aurora kinase inhibitors for anticancer therapy?
    Carpinelli P; Moll J
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):533-42. PubMed ID: 19562649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 - 2013).
    Cheung CH; Sarvagalla S; Lee JY; Huang YC; Coumar MS
    Expert Opin Ther Pat; 2014 Sep; 24(9):1021-38. PubMed ID: 24965505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.